Moderna, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Moderna, Inc. (MRNA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-02-20
- Moderna, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -0.60%.
- Moderna, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.80%.
- Moderna, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.50%, a 162.50% decline from fiscal 2022.
- Moderna, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 0.80%, a 700.00% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month |
|---|---|
| 2025-12-31 | -0.60% 10-K · filed 2026-02-20 |
| 2024-12-31 | -0.80% 10-K · filed 2026-02-20 |
| 2023-12-31 | -0.50% 10-K · filed 2026-02-20 |
| 2022-12-31 | 0.80% 10-K · filed 2025-02-21 |
| 2021-12-31 | 0.10% 10-K · filed 2024-02-23 |
| 2020-12-31 | -0.30% 10-K · filed 2023-02-24 |
| 2019-12-31 | 0.20% 10-K · filed 2022-02-25 |
| 2018-12-31 | -0.20% 10-K · filed 2021-02-26 |
| 2017-12-31 | 0.50% 10-K · filed 2020-02-27 |
| 2016-12-31 | -0.20% 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |